Press Releases

Date Title and Summary Additional Formats
Toggle Summary Concert Pharmaceuticals Announces Completion of Enrollment in First Cohort of CTP-543 Phase 2a Trial
CTP-543 is Being Evaluated in Moderate-to-Severe Alopecia Areata Phase 2a Trial On Track to Complete in Second Half of 2018 LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed enrollment of the first cohort of its Phase 2a trial
View HTML
Toggle Summary Concert Pharmaceuticals to Report Third Quarter 2017 Financial Results on November 9, 2017, and Participate at Upcoming Investor Conferences
LEXINGTON, Mass.--( BUSINESS WIRE )-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its third quarter 2017 financial results on Thursday, November 9, 2017, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m.
View HTML
Toggle Summary Concert Pharmaceuticals Announces PTAB Denies Incyte Petition Challenging CTP-543 Patent
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Patent Trials and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has denied Incyte's petition to institute inter partes review (IPR) of U.S. Patent No.
View HTML
Toggle Summary Concert Pharmaceuticals Announces Webcast at Wells Fargo Healthcare Conference
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc . (NASDAQ: CNCE) today announced that it will present a corporate overview at the Wells Fargo 2017 Healthcare Conference on Thursday, September 7, 2017 , at 11:10 a.m. EDT at the Westin Waterfront in Boston .
View HTML
Toggle Summary Concert Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Company Update
Conference Call Scheduled Today at 8:30 a.m. EDT LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2017. "We are very pleased that we have closed the CTP-656 asset purchase agreement with Vertex, which
View HTML
Toggle Summary Concert Pharmaceuticals to Report Second Quarter 2017 Financial Results on August 8, 2017
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its second quarter 2017 financial results on Tuesday, August 8, 2017 , before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m.
View HTML
Toggle Summary Vertex and Concert Pharmaceuticals Complete Asset Purchase Agreement for CTP-656
BOSTON & LEXINGTON, Mass.--( BUSINESS WIRE )-- Vertex Pharmaceuticals Incorporated  (NASDAQ: VRTX) and  Concert Pharmaceuticals, Inc.  (NASDAQ: CNCE) today announced the completion of their previously announced asset purchase agreement. Under the completed agreement, Vertex now has worldwide
View HTML
Toggle Summary Concert Pharmaceuticals Announces Termination of the HSR Act Waiting Period for CTP-656 Asset Purchase Agreement with Vertex
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the U.S. Federal Trade Commission ("FTC") has terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) for the pending sale of CTP-656 and other
View HTML
Toggle Summary FDA Lifts Clinical Hold on Concert Pharmaceuticals Clinical Trial with CTP-543
Concert to Resume Enrollment in Modified Phase 2a Trial for Alopecia Areata LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it has lifted the clinical hold on Concert's
View HTML
Toggle Summary Concert Pharmaceuticals Announces $30 Million Venture Debt Financing from Hercules Capital
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has entered into a $30.0 million venture debt financing agreement with Hercules Capital, Inc. "This non-dilutive financing further extends our existing cash runway.
View HTML